The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Hexabid     N-(6-acetamidohexyl)ethanamide

Synonyms: hmba, CHEMBL291481, CCRIS 7677, NCIMech_000063, AG-F-01686, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC95580


Psychiatry related information on NSC95580


High impact information on NSC95580


Chemical compound and disease context of NSC95580


Biological context of NSC95580


Anatomical context of NSC95580


Associations of NSC95580 with other chemical compounds


Gene context of NSC95580


Analytical, diagnostic and therapeutic context of NSC95580


  1. Enhanced replication of herpes simplex virus by hexamethylene bisacetamide. Yura, Y., Kondo, Y., Iga, H., Harada, K., Tujimoto, H., Yanagawa, T., Yoshida, H., Sato, M. J. Natl. Cancer Inst. (1991) [Pubmed]
  2. Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation. Melloni, E., Pontremoli, S., Damiani, G., Viotti, P., Weich, N., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  3. Tropomyosin synthesis accompanies formation of actin filaments in embryonal carcinoma cells induced to differentiate by hexamethylene bisacetamide. Paulin, D., Perreau, J., Jakob, H., Jacob, F., Yaniv, M. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
  4. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Richon, V.M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  5. Hexamethylene bisacetamide induces morphologic changes and increased synthesis of procollagen in cell line from glioblastoma multiforme. Rabson, A.S., Stern, R., Tralka, T.S., Costa, J., Wilczek, J. Proc. Natl. Acad. Sci. U.S.A. (1977) [Pubmed]
  6. The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide. Conley, B.A., Sewack, G.F., Egorin, M.J., Subramanyam, B., Page, J.G., Grieshaber, C.K. Cancer Chemother. Pharmacol. (1991) [Pubmed]
  7. Contributions of transcriptional and post-transcriptional mechanisms to the regulation of c-myc expression in mouse erythroleukemia cells. Nepveu, A., Marcu, K.B., Skoultchi, A.I., Lachman, H.M. Genes Dev. (1987) [Pubmed]
  8. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Yik, J.H., Chen, R., Nishimura, R., Jennings, J.L., Link, A.J., Zhou, Q. Mol. Cell (2003) [Pubmed]
  9. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. Rowinsky, E.K., Donehower, R.C., Spivak, J.L., Burke, P.J., Griffin, C.A., Jones, R.J. J. Natl. Cancer Inst. (1990) [Pubmed]
  10. Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb. Barboric, M., Kohoutek, J., Price, J.P., Blazek, D., Price, D.H., Peterlin, B.M. EMBO J. (2005) [Pubmed]
  11. Differential effects of chemical inducers on expression of beta globin genes in murine erythroleukemia cells. Nudel, U., Salmon, J.E., Terada, M., Bank, A., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1977) [Pubmed]
  12. Gene expression during terminal differentiation: dexamethasone suppression of inducer-mediated alpha 1- and beta maj-globin gene expression. Kaneda, T., Murate, T., Sheffery, M., Brown, K., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  13. Early and late changes in the glycoproteins of Friend erythroleukemia cells induced to differentiate. Gazitt, Y., Friend, C. Cancer Res. (1981) [Pubmed]
  14. Differentiation-defective mutants of mouse embryonal carcinoma cells: response to hexamethylenebisacetamide and retinoic acid. McCue, P.A., Matthaei, K.I., Taketo, M., Sherman, M.I. Dev. Biol. (1983) [Pubmed]
  15. Complementation analyses of differentiation-defective embryonal carcinoma cells. McCue, P.A., Gubler, M.L., Maffei, L., Sherman, M.I. Dev. Biol. (1984) [Pubmed]
  16. Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division. Ramsay, R.G., Ikeda, K., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  17. Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1. Kiyokawa, H., Richon, V.M., Venta-Perez, G., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  18. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Marks, P.A., Richon, V.M., Kiyokawa, H., Rifkind, R.A. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  19. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Siegel, D.S., Zhang, X., Feinman, R., Teitz, T., Zelenetz, A., Richon, V.M., Rifkind, R.A., Marks, P.A., Michaeli, J. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  20. Inducer-mediated commitment of murine erythroleukemia cells to differentiation: a multistep process. Chen, Z., Banks, J., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1982) [Pubmed]
  21. Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation. Richon, V.M., Weich, N., Leng, L., Kiyokawa, H., Ngo, L., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  22. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Breslow, R., Jursic, B., Yan, Z.F., Friedman, E., Leng, L., Ngo, L., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  23. A new group of potent inducers of differentiation in murine erythroleukemia cells. Reuben, R.C., Wife, R.L., Breslow, R., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1976) [Pubmed]
  24. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Breitman, T.R., Selonick, S.E., Collins, S.J. Proc. Natl. Acad. Sci. U.S.A. (1980) [Pubmed]
  25. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Andreeff, M., Stone, R., Michaeli, J., Young, C.W., Tong, W.P., Sogoloff, H., Ervin, T., Kufe, D., Rifkind, R.A., Marks, P.A. Blood (1992) [Pubmed]
  26. Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential. Arcangeli, A., Carlà, M., Del Bene, M.R., Becchetti, A., Wanke, E., Olivotto, M. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  27. Appearance of a chromatin protein during the erythroid differentiation of Friend virus-transformed cells. Keppel, F., Allet, B., Eisen, H. Proc. Natl. Acad. Sci. U.S.A. (1977) [Pubmed]
  28. Tiazofurin induction of mouse erythroleukemia cell hemoglobin production in the absence of commitment or changes in protooncogene expression. Sherman, M.L., Shafman, T.D., Colman, M.S., Kufe, D.W. Blood (1989) [Pubmed]
  29. Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Albanell, J., Han, W., Mellado, B., Gunawardane, R., Scher, H.I., Dmitrovsky, E., Moore, M.A. Cancer Res. (1996) [Pubmed]
  30. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  31. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Kiyokawa, H., Richon, V.M., Rifkind, R.A., Marks, P.A. Mol. Cell. Biol. (1994) [Pubmed]
  32. Regulation of murine alpha-, beta major-, and beta minor-globin gene expression. Weich, N., Marks, P.A., Rifkind, R.A. Biochem. Biophys. Res. Commun. (1988) [Pubmed]
  33. Role of microphthalmia transcription factor in regulation of melanocyte differentiation marker TRP-1. Fang, D., Setaluri, V. Biochem. Biophys. Res. Commun. (1999) [Pubmed]
  34. Expression of a gene for mouse eucaryotic elongation factor Tu during murine erythroleukemic cell differentiation. Roth, W.W., Bragg, P.W., Corrias, M.V., Reddy, N.S., Dholakia, J.N., Wahba, A.J. Mol. Cell. Biol. (1987) [Pubmed]
  35. Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans. Callery, P.S., Egorin, M.J., Geelhaar, L.A., Nayar, M.S. Cancer Res. (1986) [Pubmed]
  36. Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line. Yamashita, T., Wakao, H., Miyajima, A., Asano, S. Cancer Res. (1998) [Pubmed]
  37. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Young, C.W., Fanucchi, M.P., Declan Walsh, T., Baltzer, L., Yaldaei, S., Stevens, Y.W., Gordon, C., Tong, W., Rifkind, R.A., Marks, P.A. Cancer Res. (1988) [Pubmed]
  38. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube. Ward, F.T., Kelley, J.A., Roth, J.S., Lombardo, F.A., Weiss, R.B., Leyland-Jones, B., Chun, H.G. Cancer Res. (1991) [Pubmed]
WikiGenes - Universities